Patents Examined by Layla D Berry
  • Patent number: 11654108
    Abstract: The disclosure relates to a chewable medicated composition comprising sennosides as the active ingredient and at least one excipient, wherein the bitter taste of sennosides is masked and the composition is substantially free of sugar.
    Type: Grant
    Filed: May 2, 2022
    Date of Patent: May 23, 2023
    Assignee: MEDICATED CHEWS, LLC
    Inventor: Karthikeyan Santhanam
  • Patent number: 11649260
    Abstract: Embodiments of the present application relate to N-acetylgalactosamine-conjugated nucleosides. In particular, the N-acetylgalactosamine is installed on the nucleobase of the nucleosides through a wide variety of linkers. Methods of making N-acetylgalactosamine-conjugated nucleosides are also disclosed herein. N-acetylgalactosamine is a well-defined liver-targeted moiety and N-acetylgalactosamine-conjugated nucleosides may be used in the preparation of targeted delivery of oligonucleotide-based therapeutics.
    Type: Grant
    Filed: June 16, 2022
    Date of Patent: May 16, 2023
    Assignee: Hongene Biotech Corporation
    Inventors: Xiaoyang Guan, David Yu, Ruiming Zou, Xiaoling Zheng, John Liu, Aldrich N. K. Lau, Wing C. Poon, Gang Zhao, Gengyu Du, Yun-Chiao Yao
  • Patent number: 11649299
    Abstract: Present invention relates to a process to reduce butane sultone hydrolysis products (4-hydroxybutane-1-sulfonic acid, and bis(4-sulfobutyl) ether disodium) in sulfobutylether cyclodextrin reaction mixtures achieved with the combined use of a strong anion exchange resin having dialkyl 2-hydroxyethyl ammonium hydroxide functionality and a cation exchange resin.
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: May 16, 2023
    Assignee: CYCLOLAB CYCLODEXTRIN RESEARCH AND DEVELOPMENT LABORATORY LTD.
    Inventors: Tamas Sohajda, Gabriella Hirschbergne Szejtli, István Puskás
  • Patent number: 11643478
    Abstract: Provided is a low-molecular-weight holothurian glycosarninoglycan, with the constituent units thereof being a glucuronic acid group, an N-acetaminogalactose group and a fucose group, and a sulfate ester group or acetyl ester group thereof. Glucuronic acid and N-acetaminogalactose are interconnected via ?(1-3) and ?(1-4) glucosidic bonds to form a backbone of a disaccharide repeating structural unit, and a fucose group is connected to the backbone as a side chain. On a molar ratio basis, the ratio of the glucuronic acid group:the N-acetaminogalactose group:the fucose group is 1:(0.8-1.2):(0.6-1.2). In the structure of the low-molecular-weight holothurian glycosaminoglycan, 10-30% of glucuronic acid groups are modified, on the 2-position, with a sulfate ester group, and the rest are hydroxyl groups; and a proportion of 10-30% of fucose groups is modified, on the 2-position, with an acetyl ester group, and the rest are hydroxyl or sulfate ester groups.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: May 9, 2023
    Inventors: Yongsheng Jin, Xiujuan Ding, Wu Chen, Xiaoming Li, Junting Sun, Yihao Zhu, Xiaohua Lu, Caijuan Jin, Hua Zhou, Ningxia Wang, Yongbao Li, Qiaoyun Zhou, Jiangen Qian, Xi Chong, Yiming Yao, Yi Jiang
  • Patent number: 11642367
    Abstract: The invention relates to a novel hyperosmolar composition of hyaluronic acid for the use thereof in the treatment of corneal oedema.
    Type: Grant
    Filed: September 7, 2021
    Date of Patent: May 9, 2023
    Assignee: Horus Pharma
    Inventors: Jean-François Rouland, Martine Claret, Claude Claret
  • Patent number: 11642368
    Abstract: Compositions, methods, systems, etc., are provided for modified and/or purified fucans and corresponding fucan-containing compositions that inhibit fibrous adhesions among other advantages. The purified/modified fucans and fucan compositions have a reduced level of non-fucan components or impurities such as those found in a starting fucan composition. Such reduced undesirable components or impurities include, for example, undesired components bound to the fucan and compounds in the composition that are not a part of or bound to the fucan.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: May 9, 2023
    Assignee: ARC Medical Inc.
    Inventors: Christopher Michael Kevin Springate, Ian Millet, Sailesh Haresh Daswani, Hesong Sun, Aileen Shao Ting Yang, Hoi Ting Wong
  • Patent number: 11633414
    Abstract: The invention relates to compositions of nicotinoyl ribosides and nicotinamide riboside derivatives and their methods of use. In some embodiments, the invention relates to methods of making nicotinoyl ribosides. In some embodiments, the invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinoyl riboside. In further embodiments, the invention relates to methods of using nicotinoyl ribosides and nicotinamide riboside derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival.
    Type: Grant
    Filed: July 27, 2021
    Date of Patent: April 25, 2023
    Assignee: Cornell University
    Inventors: Anthony A. Sauve, Tianle Yang Redanz
  • Patent number: 11633489
    Abstract: Disclosed herein is a pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of an iron deficiency of a fetus or an infant, wherein the iron carbohydrate complex is administered to the mother of the fetus or infant.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: April 25, 2023
    Assignee: PHARMACOSMOS HOLDING A/S
    Inventors: Lars Lykke Thomsen, Tobias S. Christensen, Hans Andreasen
  • Patent number: 11633423
    Abstract: This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.
    Type: Grant
    Filed: September 16, 2022
    Date of Patent: April 25, 2023
    Assignee: Mandos LLC
    Inventors: Bernardus Nicolaas Machielse, Allan Darling
  • Patent number: 11634449
    Abstract: Provided herein are methods of preparing macrolides by the coupling of an eastern and western half, followed by macrocyclization, to provide macrolides, including both known and novel macrolides. Intermediates in the synthesis of macrolides including the eastern and western halves are also provided. Pharmaceutical compositions and methods of treating infectious diseases and inflammatory conditions using the inventive macrolides are also provided. A general diastereoselective aldol methodology used in the synthesis of the western half is further provided.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: April 25, 2023
    Assignee: President and Fellows of Harvard College
    Inventors: Andrew G. Myers, Ian Bass Seiple, Ziyang Zhang
  • Patent number: 11633421
    Abstract: Certain embodiments of the invention provide a method for improving maternal and/or offspring health, comprising administering an effective amount of a nicotinamide adenine dinucleotide (NAD) precursor to a female mammal (e.g., pregnant or lactating female mammal).
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: April 25, 2023
    Assignee: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Charles M. Brenner, Po Hien Ear, Ankita Chadda, Marie E. Migaud, Hanna Stevens
  • Patent number: 11634447
    Abstract: The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: April 25, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Yeeman K. Ramtohul, Sanjoy Kumar Das, Caroline Cadilhac, Thumkunta Jagadeeswar Reddy, Louis Vaillancourt, Michel Gallant, Bingcan Liu, Evelyne Dietrich, Frederic Vallee, Julien Martel, Carl Poisson
  • Patent number: 11628183
    Abstract: Compositions, methods, systems, etc., are provided for modified and/or purified fucans and corresponding fucan-containing compositions that inhibit fibrous adhesions among other advantages. The purified/modified fucans and fucan compositions have a reduced level of non-fucan components or impurities such as those found in a starting fucan composition. Such reduced undesirable components or impurities include, for example, undesired components bound to the fucan and compounds in the composition that are not a part of or bound to the fucan.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: April 18, 2023
    Assignee: ARC Medical Ine.
    Inventors: Christopher Michael Kevin Springate, Ian Millet, Sailesh Haresh Daswani, Hesong Sun, Aileen Shao Ting Yang, Hoi Ting Wong
  • Patent number: 11623939
    Abstract: The present invention is directed to a process for purifying natamycin, to an all-trans polyene amphoteric macrolide, to a composition comprising said polyene amphoteric macrolide and to a process for preparing said polyene amphoteric macrolide.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: April 11, 2023
    Assignee: DSM IP ASSETS B.V.
    Inventors: Alexander Lucia Leonardus Duchateau, Peter Philip Lankhorst, Willebrordus Bernardus Van Scheppingen
  • Patent number: 11623938
    Abstract: The present invention belongs to the field of biomedicine, specifically relates to the field of targeting medicine. More specifically, the present invention relates to a liver-targeting compound having thyroid hormone receptor agonist characteristics and a pharmaceutical composition thereof. The compound is a compound represented by formula (1). The compound can be used for treating and/or preventing diseases caused by thyroid hormone dysregulation, and can also effectively reduce lipids in plasma and liver cells.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: April 11, 2023
    Assignee: KYLONOVA (XIAMEN) BIOPHARMA CO., LTD.
    Inventors: Kunyuan Cui, Shengjun Wang, Yanchun Du
  • Patent number: 11618764
    Abstract: Reagents, methods, and kits for assaying enzymes associated with lysosomal storage diseases MPS-I, MPS-II, MPS-IIIA, MPS-IIIB, MPS-IVA, MPS-VI, and MPS VII.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: April 4, 2023
    Assignee: University of Washington through its Center for Commercialization
    Inventors: Michael H. Gelb, Arun Babu Kumar, Frances Hocutt, Zdenek Spacil, Mariana Natali Barcenas Rodriguez, Frantisek Turecek, C. Ronald Scott
  • Patent number: 11617763
    Abstract: The present invention relates to the medical use of polysulfated polysaccharides and compositions thereof for the treatment of disease or disorders associated with bone marrow pathologies in the musculoskeletal system of a mammal. In particular, the invention relates to use of polysulfated polysaccharides, such as pentosan polysulfate, in treatment of bone marrow edema lesions or spinal Modic Endplate Changes as assessed by magnetic resonance imaging (MRI).
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: April 4, 2023
    Assignee: PARADIGM BIOPHARMACEUTICALS LTD
    Inventors: Ravi Krishnan, Paul Rennie
  • Patent number: 11613553
    Abstract: The present disclosure generally describes methods of preparing 1?-cyano nucleosides, such as a compound of Formula (I). For example, the compound of Formula (I) can be prepared from a compound of Formula (II-a) in a flow reactor.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: March 28, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Pavel R. Badalov, Stacy Bremner, Matthew R. Chin, Detian Gao, Nolan Griggs, Lars V. Heumann, Chiajen Lai, Robert R. Milburn, Sankar Mohan, Sean T. Neville, Bing Shi, Andrew C. Stevens, Nicholas A. J. Uhlig, Tiago Vieira, Todd A. Wenderski
  • Patent number: 11608389
    Abstract: The subject of this invention are native forms of fucoidan polysaccharide, desulfated fucoidan and derivatives obtained by processing to the level of fucose-oligosaccarides containing preferentially, but not exclusively less than 20 monosaccaride fucose units alpha-linked by a glycosidic bond, with an average molecular weight of preferentially less than 3 kDa. The poly- and oligosaccarides that are described according to the invention are natural and safe, and are used as a dietary supplement for the use in prevention and treatment of pathologies associated with Noroviruses or Rotaviruses, Salmonella sp. or Pseudomonas aeruginosa or Campylobacter jejuni and other enteroviruses and enteric pathogens that cause bacterial gastroenteritis, as well as in the food production process. The invention also relates to a method for the desulfation and fragmentation of fucoidans to generate desulfated poly- or oligo-fucoses.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: March 21, 2023
    Inventors: Bojan Pavlovic, Franz-Georg Hanisch, Cem Aydogan
  • Patent number: 11597744
    Abstract: Disclosed are chiral phosphoramidite auxiliary compositions for diastereoselective synthesis of stereochemically enriched oligonucleotides, and nucleoside phosphoramidite compounds comprising the same. Exemplary structures of the chiral phosphoramidite auxiliary compositions include Formulas (IA) and (IB).
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: March 7, 2023
    Assignee: SIRIUS THERAPEUTICS, INC.
    Inventors: Sukumar Sakamuri, Curt W. Bradshaw, Dingguo Liu, Laxman Eltepu